LONDON, UK: RTW Venture Fund’s portfolio company, Acelyrin, Inc. announced the pricing of its initial public offering (IPO) and admission to trade on Nasdaq Global Market under the ticker symbol “SLRN.” The IPO raised $540 million by offering 30 million shares at $18.00 per share. The company’s share price traded up by 30.55% on the…
All posts tagged RTW Venture Fund
Apogee Therapeutics as completes $149 million Series B financing round
LONDON, UK: Apogee Therapeutics LLC has completed $149 million Series B financing round. RTW Venture Fund, alongside other investment vehicles of RTW Investments LP participated in the Series B financing round together with other investors. Apogee Therapeutics is a privately held pre-clinical stage biotech advancing potentially best-in-class therapies for immunological and inflammatory disorders. The company…